---
title: "Invivyd, Inc. (IVVD.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/IVVD.US.md"
symbol: "IVVD.US"
name: "Invivyd, Inc."
industry: "Biotechnology"
---

# Invivyd, Inc. (IVVD.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [invivyd.com](https://invivyd.com) |

## Company Profile

Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company’s pipeline includes PEMGARDA (pemivibart) injection, a half-life extended investigational monoclonal antibody...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-03-02T04:30:16.000Z

**Overall: C (0.44)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 117 / 406 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 332.71% |  |
| Net Profit YoY | 73.41% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 5.12 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 476.56M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 50.04M |  |


**Multi Score**: C

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -67.94% | E |
| Profit Margin | -119.63% | E |
| Gross Margin | 91.71% | A |

#### Growth Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 332.71% | A |
| Net Profit YoY | 73.41% | A |
| Total Assets YoY | -14.06% | E |
| Net Assets YoY | 11.91% | B |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -83.59% | D |
| OCF YoY | 332.71% | A |

#### Operating Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.33 | D |

#### Debt Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 33.12% | B |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Invivyd, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-67.94%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-119.63%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "91.71%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "A",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "332.71%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "73.41%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-14.06%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "11.91%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-83.59%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "332.71%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "D",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.33",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "B",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "33.12%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 02 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 03 | MiMedx (US.MDXG) | A | B | A | B | B | A |
| 04 | Rigel Pharma (US.RIGL) | A | A | A | C | B | A |
| 05 | OpGen (US.OPGN) | B | A | A | A | B | A |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -7.96 | 432/606 | - | - | - |
| PB | 5.12 | 307/606 | 6.21 | 3.97 | 1.51 |
| PS (TTM) | 9.52 | 154/606 | 10.58 | 5.15 | 2.50 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-25T05:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 3 | 75% |
| Overweight | 0 | 0% |
| Hold | 1 | 25% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.69 |
| Highest Target | 10.00 |
| Lowest Target | 10.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/IVVD.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/IVVD.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/IVVD.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.